HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that an overview of the Company’s business strategy will be given at the Bank of America Merrill Lynch 2012 Health Care Conference being held at Encore at the Wynn Hotel in Las Vegas, Nevada. The Spectrum Pharmaceuticals presentation is at 8:00am Pacific Time on Tuesday, May 15, 2012.
The live webcast of Spectrum's corporate presentation will be available at http://www.sppirx.com.
About Spectrum Pharmaceuticals, Inc.
Spectrum
Pharmaceuticals, a biotechnology company with a primary focus in
oncology and hematology, currently markets two oncology drugs, FUSILEV®
(levoleucovorin) for Injection and ZEVALIN® (ibritumomab
tiuxetan) Injection for intravenous use. In addition, Spectrum has two
drugs, belinostat and apaziquone, in late stage development and a
diversified pipeline of novel drug candidates in earlier stages of
development. The Company’s strategy is comprised of acquiring,
developing and commercializing a broad and diverse pipeline of
late-stage clinical and commercial drug products. The Company has
aggressive business development and commercial operation teams that
support a robust drug development program encompassing clinical
development, medical research, regulatory affairs, biostatistics and
data management. The Company also leverages the expertise of its
worldwide partners to assist in the execution of its strategy. For more
information, please visit the Company’s website at www.sppirx.com.
Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new applications to the FDA may not receive approval, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.®, ZEVALIN®,
and FUSILEV® are registered trademarks of
Spectrum Pharmaceuticals, Inc.
REDEFINING CANCER CARE™ and
the Spectrum Pharmaceutical logos are trademarks owned by Spectrum
Pharmaceuticals, Inc.
© 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.